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Summary 
Esophagus squamous cell carcinoma (ESCC) is an intractable digestive organ cancer that has proven 
difficult to treat despite multidisciplinary therapy, and the new treatment strategy is demanded. 
Metformin is used for type 2 diabetes mellitus and its antitumor effects have been reported recently. 
Metformin exerts antitumor effects in various respects, such as inhibiting inflammation, tumor growth 
and epithelial-mesenchymal transition (EMT). However, few reports have described the efficacy of 
metformin on ESCC, and their findings have been controversial. We analyzed the antitumor effects of 
metformin and clarified its effects on anti-inflammation, growth suppression and EMT inhibition.  
The activation of NF-κB, the major transcription factor induced by inflammation was investigated by 
immunostaining. We found that the localization of NF-κB in the nucleus was reduced after metformin 
treatment. This suggests that metformin inhibited the activation of NF-κB. Metformin inhibited tumor 
growth and induced apoptosis in ESCC cell lines. Associated with EMT, we examined the cell motility 
by a wound healing assay and the epithelial marker E-cadherin expression of various ESCC cell lines 
by Western blotting. Metformin inhibited the cell motility and induced E-cadherin expression.  
In conclusion, metformin showed multiple antitumor effects such as growth suppression, invasion 
inhibition, and to control EMT by inhibiting NF-κB localization on ESCC. Further exploration on the 
marker of treatment efficacy and combinatory therapy could bring out the possibility for novel 
treatment to use metformin on ESCC. 
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EMT epithelial mesenchymal transition 
ESCC esophageal squamous cell carcinoma 
LKB1 liver kinase B1 
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Introduction 
Esophagus squamous cell carcinoma (ESCC) is an intractable digestive organ cancer that shows a high 
incidence in East Asia. It remains difficult to treat despite multidisciplinary therapy, including 
operation, chemotherapy and radiotherapy. In particular, tolerance to  chemotherapy and a tendency 
toward metastasis even when tumors are superficial are major factors making treatment difficult(1). 
We have recently been conducting research focused on epigenetics and reported that microRNA-375 
induced by histone acetylation had ESCC restraint action(2). We searched the drugs which induce the 
similar gene expression style by connectivity map and found metformin. It restrained the increase of 
ESCC cell lines, TE2 and T.Tn.(3) 
 
Metformin is an oral biguanide that has been used to treat type 2 diabetes mellitus (DM) worldwide 
for a long time, and the antitumor effects of metformin have been reported recently(4). The main target 
of metformin is regarded as AMP-activated kinase (AMPK), which has various functions. Metformin 
induces the activation of liver kinase B1 (LKB1), which phosphorylates and activates AMPK (5). 
However, details about the drug’s activities remain unclear. 
 
DM increases the risk of developing cancer, and possible biological links between DM and cancer 
comprise hyperinsulinemia, hyperglycemia and fat-induced chronic inflammation (6). Patients treated 
with metformin have shown a lower incidence of cancer than the other treatment groups (7). In addition, 
metformin reportedly affects various cancers, such as gastric cancer(8), non-small lung cancer(9), 
Colorectal cancer(10). Metformin exerts its antitumor effects in various ways, including inducing cell 
cycle arrest(11), enhancing the immune system(12), inhibiting epithelial-mesenchymal transition 
(EMT) (13), inducing hypersusceptibility for the chemotherapy(14), and inhibiting inflammatory 
signals via nuclear factor (NF)-κB/Transforming growth factor-β (TGF-β)(15).  
 
EMT plays a key role in inducing stationary tumor cells to migrate and invade and metastasize to other 
organs(16). E-cadherin is the most important marker of epithelial cells and is used widely to determine 
EMT inhibition(17). It has recently been shown that metformin inhibits migration or invasion by 
affecting EMT in various tumors, such as cholangiocarcinoma(18), cervical carcinoma(19), thyroid 
cancer(20) and melanoma(21). 
 
Regarding the clinical antitumor effects of metformin on ESCC. Van De Voorde reported that the use 
of metformin was associated with an improved overall and distant metastasis-free survival rate in 
patients with esophageal cancer (22). In contrast, Spierings reported that the metformin use in patients 
receiving neoadjuvant chemo(radio)therapy for potentially curable esophageal cancer did not show 
better outcomes of pathological response rates or an improved overall or disease-free survival rate (23). 
The antitumor effect of metformin on ESCC remains controversial. Few reports have examined the 
mechanism underlying the antitumor effect of metformin on ESCC.  
 
It has already been reported that metformin affects the tumor growth in ESCC via cell cycle arrest (24) 
(25). Furthermore, one report described the effect of EMT inhibition in ESCC, outlining the inhibitory 
effects of radiation exposure for EMT via TGF-β signaling (26). These reports suggest that metformin 
has effects on growth inhibition as well as EMT inhibition, which is associated with invasion and 
metastasis, and the enhancement of chemotherapy sensitivity. However, few reports have found that 
metformin affects EMT in ESCC, and the results of such studies are eagerly awaited. 
 
Given the above, we analyzed the antitumor effect of metformin, including anti-inflammation, growth 
suppression and EMT inhibition, and explored the mechanisms by which such effects are achieved.  
Material and Methods 
ESCC cell culture and regents 
The human ESCC cell lines were cultured in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-
12 Ham (Sigma-Aldrich, St. Louis, MO, USA) with 10% Fetal Bovine Serum (FBS) in a humidified 
incubator at 37 °C in a 5% CO2. We used the human ESCC cell lines TE1, TE2, TE4, TE5, TE6, TE8, 
TE10, TE11, TE14, TE15 and T.Tn. We also used TE2-Fluorescent Ubiquitination-based Cell Cycle 
Indicator (FUCCI) cells. The T.Tn cells were provided by the Japanese Cancer Research Resources 
Bank. TE1, TE2, TE4, TE5, TE6, TE8, TE10, TE11, TE14 and TE15 cells were kindly provided by 
Dr. T. Nishihira (Tohoku University, Sendai, Japan).  
Metformin was obtained from Sigma Chemical Co. (St. Louis, MO, USA). Penicillin and streptomycin 
were obtained from North China Pharmaceutical Group Corp (Shijiazhuang, China). We obtained 
0.05% trypsin-EDTA and FBS from Invitrogen Life Technologies (Carlsbad, CA, USA).  
Antibodies against AMPK and LKB1 were purchased from Cell Signaling (MA, USA), that against 
E-cadherin was purchased from Santa Cruz Biotechnology (TX, USA), that against NF-κB p65 and 
beta-actin were purchased from abcam (Cambridge, United Kingdom), and a rabbit-secondary 
antibody was purchased from Invitrogen.  
 
Cell viability assay 
The inhibitory influence of cell proliferation by administrating metformin was evaluated by the cell 
viability using Cell Counting Kit-8 (CCK-8) (Dojindo, Kumamoto, Japan). Cells were seeded in 96-
well plates at 5×103 cells per well and cultured 24 hours. Then the cells were exposed to various 
concentrations of metformin for 72 hours, and the antiproliferative effects were determined using a 
CCK-8. The absorbance was determined at 450 nm using a microplate reader. 
 
Tumor xenograft model  
Six-week-old Balb/C nude mice were used to establish a TE2-FUCCI and TE14 tumor model. Nude 
mice were housed in a specific-pathogen-free facility. TE2-FUCCI and TE14 cells were harvested and 
injected subcutaneously into the dorsal area at 5×106 cells. The mice were randomized into control 
group and treatment group (TE2-FUCCI; 7 mice per group and TE14; 6 mice per group). After 14 
days, the tumors became palpable and the mice in the treatment group were administered metformin 
(5 mg/mice) via intraperitoneal injection, while those in the control group were administered phosphate 
buffered saline (100 μl) five times a week. Treatments were performed for 28 days, and the tumor 
volumes (volume=0.5×width2×length) were determined regularly.  
 
Apoptosis in vivo 
Tumor tissues were embedded in paraffin and then sectioned at 4 μm and deparaffinized. Apoptosis 
was detected based on an analysis of DNA fragmentation using a terminal deoxynucleotidyl 
transferase-mediated nick end labeling assay (TUNEL) with an In situ Apoptosis Detection kit (Takara, 
Tokyo, Japan). The apoptotic index was defined as the number of positive cells among TE2-FUCCI 
tumor xenograft models in arbitrary microscopic fields (6 mice per group). 
 
Western blotting 
Anti-human LKB1 mouse monoclonal immunoglobulin (Ig) G and anti-human AMPK mouse 
monoclonal IgG and anti-human E-cadherin rabbit polyclonal IgG were used as primary antibodies. 
The cells were harvested with the indicated concentrations of metformin for 24 h and lysed with 
radioimmunoprecipitation assay (RIPA) buffer. The Western blot analysis was performed on an XV 
PANTERA Gel 7.5–15% (DRC, Tokyo, Japan). The proteins in the gels were transferred 
electrophoretically onto nitrocellulose membranes. The membranes were incubated with primary 
antibodies against LKB1 and AMPK and E-cadherin and β-actin. The expression of each protein was 
detected using secondary antibodies conjugated to peroxidase-labeled polymers. Bands were 
visualized using the Amersham ECL Prime Western blotting reagent (GE Healthcare Life Sciences, 
Uppsala, Sweden). Densitometry was done using the ImageJ software program (NIH, Bethesda, MD, 
USA). 
 
Wound healing test 
T.Tn and TE2-FUCCI cells were scratched after metformin treatment for 24 h, harvested with the same 
concentration of metformin, and photographed digitally at 0 and 22 h from scratch. The intercellular 
space was measured at random, and the relative value was calculated on the basis of the gap at the time 
when the cells were scratched. 
Cell migration and invasion assay 
TE2, TE14 and T.Tn cells were used in cell migration and invasion assay. 
Cell migration assay was determined using the insert of micropore membrane filter with 8 μm pores 
(BD Biosciences, NJ, USA). 5 × 104 cells with DMEM without FBS were seeded into the 24-well size 
insert and DMEM containing 10% FBS was added into the lower chamber as the attractant. After 24 
hours the cells on the upper side of membrane were removed with cotton swabs and the membranes 
were fixed and stained using the Diff-Quik reagent (International Reagents, Kobe, Japan). 
Cell invasion assay was determined using collagen type I (CORNING, NY, USA) -coated micropore 
membrane filter with 8 μm pores (BD Biosciences). The collagen I-coated chambers were prepared as 
described previously(27). The procedure of cell seeding and the attractant adding was same with cell 
migration assay, and the membrane was fixed and trained after 48hours. 
Cell migration/invasion was quantified by counting the average number of migrated/invaded cells in 
random high-powered fields per filter. 
 
Fluorescence microscopy 
TE2 cells cultured on coverslips were fixed in 4% paraformaldehyde for 10 min and permeabilized 
with 0.1% Triton X-100 for 5 min. After blocking with 3% FBS/PBS, the cells were incubated with 
anti-human NF-κB p65 rabbit antibody at 37 °C for 60 min. The cells were then incubated with Alexa 
Fluor 488 gout anti-rabbit IgG (Invitrogen) as the secondary antibody. ProLong Gold antifade reagent 
with DAPI (Invitrogen) was used for the counterstaining of DNA. 
 
Statistical analyses  
Data were analyzed by t tests conducted using the Excel software program (Microsoft, Washington, 
USA). P<0.05 was considered to indicate significance. 
 
 
 
Results 
 
NF-κB activity 
The effect of metformin on the expression and intracellular localization of NF-κB on TE2 cells was 
examined by immunostaining. NF-κB existed in both the cytoplasm and the nucleus in the control 
group, but the NF-κB expression in the nucleus was lower in the group treated with 5 mM metformin. 
This result suggests that metformin affects the nuclear import of NF-κB (Fig. 1). 
 
 
Fig. 1. Metformin affects the intracellular localization of NF-κB.  
(A)The local existence in the cell of NF-κB was evaluated by immunostaining TE2 cells. Images of 
immunohistochemistry staining with NF-kB (a,b,c,d) and the nucleus was stained by DAPI (e,f). 
Group: (a, c, e) control cells, (b, d, f) metformin treated cells. Magnification: (a,b) ×200, (c,d,e,f,) 
×1000.  
(B)The brightness in the cytoplasm and nucleus of each cell was quantified using the Image J program, 
and the N/C ratio was calculated (n=5). The NF-κB expression in the nucleus was significantly lower 
in the metformin-treated group than in the control group (p=0.0422). 
Growth inhibition 
 Proliferation assay and AMPK and LKB1 protein expression in ESCC cell lines 
Metformin inhibited cell proliferation in all ESCC cell lines (TE1, TE2, TE4, TE5, TE6, TE8, TE10, 
TE11, TE14, TE15 and T.Tn) in a dose-dependent manner. However, there was a marked difference in 
the sensitivity among these cell lines (Fig. 2A). The AMPK and LKB1 protein expression as evaluated 
by Western blotting in the steady state varied among cell lines. However, there was no significant 
correlation between their expression and metformin sensitivity (Fig. 2B).  
 
Fig. 2. Proliferation assay and AMPK and LKB1 protein expression in ESCC cell lines.  
(A) A proliferation assay using CCK-8 (n=3). Metformin was administrated to ESCC cells for 72 hours. 
Bar; S.D. 
(B) Western blotting analysis of AMPK and LKB1 protein expression at steady state in these ESCC 
cell lines 
 Tumor growth and apoptosis in vivo 
The relative tumor volume was significantly smaller in the metformin-treated group than in the control 
group on both TE2-FUCCI (p=0.033) (Fig. 3A) and TE14 (p=0.034) (Fig. 3B).  
There was no difference in body weight change of the mice between control group and metformin 
administrated group in both TE2-FUCCI (Fig. 3C) and TE14 (Fig 3D). 
On TE2-FUCCI xenograft model, the apoptotic cells were detected by TUNEL stain (brown nuclear 
cell: positive cells, green nuclear cell: negative), there were significantly more apoptotic cells in the 
tumors in the metformin-treated group than in the control group (p=0.0257) (Fig. 3E, 3F). 
 
Fig. 3. Tumor growth and apoptosis in vivo.  
The relative tumor volume on the xenograft model of (A) TE2-FUCCI (n=7) and (B) TE14 (n=6). 
Both TE2-FUCCI and TE14 model, the relative tumor volume was significantly smaller in the 
metformin-treated group than in the control group (TE2-FUCCI: * p=0.033, TE14: ** p=0.034). Bar: 
S.E. The body weight of the xenograft model at day14 and day42 after injection of (C) TE2-FUCCI 
(n=7) and (D) TE14 (n=6). There were no significant difference between the control group and the 
metformin-treated group (TE2-FUCCI: * p=0.41, TE14: ** p=0.56). Bar: S.E. 
 Fig. 3. Tumor growth and apoptosis in vivo.  
(E) On TE2-FUCCI xenograft model, the apoptotic cells were detected by TUNEL stain (brown 
nuclear cell: positive, green nuclear cell: negative).  
(F) Average number of the apoptotic cells per view in the tumor on TE2-FUCCI xenograft model (n=6). 
There were significantly more apoptotic cells in the tumors in the metformin-treated group than in the 
control group (* p=0.0257). Bar: S.D. 
 
EMT inhibition 
EMT is associated with malignancy and increased cell motility as the ability of migration and invasion. 
The wound healing assay and the cell migration/invasion assay are useful to evaluate the cell motility.  
 
 Wound healing assay 
The cell migration in the high-concentration metformin-treated group (5 or 10 mM) was significantly 
lower than in the control group, but the migration in the low-concentration metformin-treated group 
(1 or 3 mM) did not show a significant difference from the control group (Fig. 4A, 4B). These results 
suggest that metformin inhibited the TE2-FUCCI and T.Tn cell motility in a dose-dependent manner. 
Furthermore, a larger proportion of cells were in G0/G1 in the high-concentration metformin-treated 
group than in the control group. 
 
 Fig. 4. Wound healing scratch assay.  
(A) The T.Tn and TE2-FUCCI cells were treated with metformin and captured after 22 hours from 
scratch. Magnification: ×200 
The relative distance of the intracellular space is shown (n=7). Bar: S.D. Cell strains: (B) T.Tn, (C) 
TE2-FUCCI. 
 
 Cell migration/invasion assay 
In the migration assay, the number of penetrating cells through the membrane were significantly 
decreased by administrating metformin in a dose dependent manner on TE2 (Fig. 5A), * p=0.01 (0mM 
vs 3mM), and ** p=0.01 (0mM vs 5mM). On the other hand, it was slightly less but not significant on 
T.Tn (Fig. 5B), * p=0.88 (0mM vs 3mM), and ** p=0.16 (0mM vs 5mM). 
In the invasion assay, the number of penetrating cells through the membrane coated with collagen-I 
were also decreased by administrating metformin in a dose dependent manner on TE2 (Fig. 5A) , * 
p=0.23 (0mM vs 3mM), and ** p=0.04 (0mM vs 5mM). On the other hand, it was also slightly less 
but not significant on T.Tn (Fig. 5B) , * p=0.18 (0mM vs 3mM), and ** p=0.13 (0mM vs 5mM). 
Metformin administration significantly decreased the migration/invasion ability of the cells in TE2, 
but this tendency was not clearly observed in T.Tn. 
 
 
Fig. 5. Cell migration/invasion assay.  
The cell migration assay was performed. (A) TE2 cells, * p=0.01 (0mM vs 3mM), and ** p=0.01 
(0mM vs 5mM). (B) T.Tn cells, * p=0.88 (0mM vs 3mM), and ** p=0.16 (0mM vs 5mM).  
The cell invasion assay was performed. (C) TE2 cells, * p=0.23 (0mM vs 3mM), and ** p=0.04 (0mM 
vs 5mM). (D) T.Tn cells, * p=0.18 (0mM vs 3mM), and ** p=0.13 (0mM vs 5mM).  
 
 
 E-cadherin expression 
E-cadherin is expressed by epithelial cells and so is an important marker of EMT. We first evaluated 
the effect of metformin on the induction of E-cadherin expression by Western blotting. In TE2 cells, 
metformin induced E-cadherin protein expression in a dose-dependent manner (Fig. 6A).  
Next, we examined the E-cadherin expression in TE1, TE4, TE5, TE6, TE8, TE11, TE14 and T.Tn. 
cells. On TE1, TE8, TE11 and T.Tn. cells, E-cadherin expression was increased, but the other ESCC 
cell lines did not show a similar tendency (Fig. 6B).  
 
 
Fig. 6. Western blotting analysis of E-cadherin protein expression in ESCC cell lines.  
(A) Metformin induced E-cadherin expression in a dose-dependent manner in TE2 cells.  
(B) Metformin (3mM) induced E-cadherin expression in several ESCC cell lines. 
 
 
Discussion 
 
In this study, we found that metformin affected the tumor malignancy via action on tumor growth and 
EMT, and these effects may have been induced by inhibiting NF-κB activity. Cell cycle arrest and 
TGF-β signaling have already been reported as antitumor mechanisms of metformin, but NF-κB also 
participates in the antitumor effects of metformin. 
 
It has been reported that metformin inhibits cell proliferation on ESCC cell lines, but our evaluation 
of the effects on proliferation of various ESCC cell lines showed that the metformin sensitivity varied 
among lines. Surprisingly, there was no significant correlation between the metformin sensitivity and 
the expression of AMPK or LKB1. Other determinatives and various molecular functions may 
influence the metformin sensitivity of cancer cells. Although the main target of metformin is thought 
to be AMPK, it has also been reported that acts on other pathways as MAPK pathway and NF-kB(28). 
These pathways may be also activated by metformin apart from AMPK activation. There is a big 
question that the anti-tumor effect of metformin is different depending on cancer type, but the answer 
may be which pathway is more likely to be activated. 
 
It has been reported that tumor growth is inhibited and apoptosis induced by metformin in vivo, and in 
this study, a similar tendency was shown. Based on these in vitro and in vivo results, metformin appears 
to affect the tumor size by inhibiting cell proliferation and inducing apoptosis.  
 
The expression of E-cadherin, the most important marker of epithelial cells, was induced by metformin 
in various ESCC lines, but the sensitivity to metformin differed among those cell lines. The expression 
of LKB1 or AMPK did not show clear correlations with metformin sensitivity. As mentioned before, 
this result also suggests that other factors may exist that influence the sensitivity to metformin. 
 
Various reports have examined the mechanisms by which metformin affects the EMT, such as via 
TGF-β or mTOR (20, 26). It has also been reported that EMT is induced by NF-κB (29). NF-κB is an 
important nuclear factor that is associated with various physiological phenomena, including acute or 
chronic inflammation (30), cell proliferation, suppressing apoptosis(31) and the immune response(32). 
NF-κB is known to be constantly active in many malignant tumors and is a central signaling hub in 
inflammation-mediated tumor promotion and metastasis (33). In ESCC, the clinical correlation of the 
NF-κB expression and prognosis has been examined, and ESCC patients with NF-κB-positive tumors 
showed a poor survival (34). 
 
Because metformin exerts multiple effects, including inhibiting tumor growth and EMT and inducing 
apoptosis, the correlation of metformin and NF-κB, which also has various physiological functions, 
has received attention. There are some reports that metformin inhibits NF-κB in several cancers, such 
as pancreatic tumor (15), bladder Cancer (35), and cholangiocarcinoma (36). This is the first report to 
find that metformin inhibits NF-κB in ESCC. Carcinogenesis occurs in multiple phases as tumor 
initiation, promotion and progression. NF-κB induces inflammation, which is a very important aspect 
of tumor promotion. Therefore, metformin may inhibit tumor promotion by inactivating NF-κB. 
 
There are many signals that are associated with EMT (37). TGF-β, which strongly promotes EMT, was 
reported to be inhibited by metformin in ESCC cell lines. However, in our study, the mRNA expression 
of TGF-β showed no significant change on treatment with metformin (data not shown), suggesting that 
some other EMT-inducing signal is likely inhibited by metformin. The change in the intracellular 
localization of NF-κB by metformin may show that metformin exerts its antitumor effect by inhibiting 
EMT via NF-κB. 
 
As often pointed out, the concentration at which metformin exerts its effects is different between in 
vivo and in vitro. Here we reported that 5mg/mouse (250mg/kg) of metformin was administered to 
mice, in which case the blood concentration of metformin is reported to be 5μM (38). The blood 
concentration of metformin in patients taking metformin is reported to be 10 μM(39). The metformin 
concentration that showed in vitro effect was much higher than the metformin concentration that 
showed effect in vivo. Therefore we have to take care to determine whether the results obtained in vitro 
reflect the effects in vivo. As the reason for that, too high glucose concentration in the medium may 
associate with the difference in metformin concentration. It is reported that the concentration of 
glucose in the solid tumor is 0.5mM or less(40), and cells cultured at low glucose concentration have 
higher metformin sensitivity for cell viability than at high glucose concentration(41). As a result, 
metformin may act specifically on solid tumor cells rather than normal cells and it is also thought that 
the high glucose concentration masks the antitumor effects of metformin to some extent in vitro. 
Although the administered concentration of metformin was higher than in vivo, the antitumor effects 
that metformin exhibited in vitro in this report could be considered sufficiently to show the same effects 
in vivo, because these effects were recognized even under the influence of high glucose. In this report, 
the medium with the normal glucose concentration was used, but the use of the medium with the low 
glucose concentration may be more suitable for examining the antitumor effect in vivo. 
 
In our study, metformin showed antitumor effects by inhibiting cell proliferation, tumor growth and 
EMT and inducing apoptosis in ESCC cell lines and xenograft models. These effects may have been 
induced by inhibiting NF-κB activation on ESCC. Therefore, metformin may be useful for treating 
ESCC, and further studies are expected. 
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